{"id":"canagliflozin-sglt2i","safety":{"commonSideEffects":[{"rate":"10–15","effect":"Genital mycotic infections"},{"rate":"8–12","effect":"Urinary tract infections"},{"rate":"5–10","effect":"Polyuria/polydipsia"},{"rate":"3–5","effect":"Hypotension"},{"rate":"<1","effect":"Diabetic ketoacidosis (rare)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"SGLT2 (sodium-glucose cotransporter 2) is responsible for reabsorbing filtered glucose back into the bloodstream in the proximal tubule of the kidney. By inhibiting this transporter, canagliflozin prevents glucose reabsorption, causing increased urinary glucose excretion (glycosuria) and a net reduction in blood glucose levels. This mechanism is insulin-independent and also promotes modest natriuresis and weight loss.","oneSentence":"Canagliflozin blocks the SGLT2 transporter in the kidney to reduce glucose reabsorption, allowing excess glucose to be excreted in urine and lowering blood sugar.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:40:42.709Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"},{"name":"Reduction of cardiovascular death and hospitalization for heart failure in patients with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors"}]},"trialDetails":[{"nctId":"NCT07157475","phase":"","title":"Vascular Complications in Patients Undergoing Peripheral Revascularization and Taking SGLT-2 Inhibitors","status":"RECRUITING","sponsor":"Wroclaw Medical University","startDate":"2025-07-01","conditions":"Peripheral Arterial Disease(PAD)","enrollment":300},{"nctId":"NCT07325435","phase":"PHASE4","title":"Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists","status":"ACTIVE_NOT_RECRUITING","sponsor":"MaryAnn Banerji","startDate":"2024-12-21","conditions":"Type 2 Diabetes (T2DM)","enrollment":60},{"nctId":"NCT06528405","phase":"PHASE2","title":"The Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors in Patients With Acute Kidney Disease","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2024-11-21","conditions":"Acute Kidney Injury","enrollment":264},{"nctId":"NCT07309094","phase":"","title":"Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD","status":"RECRUITING","sponsor":"Cardenal Herrera University","startDate":"2023-09-15","conditions":"Chronic Kidney Disease stage3, Chronic Kidney Disease stage4, Chronic Kidney Disease Stage 1","enrollment":250},{"nctId":"NCT05220917","phase":"","title":"Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2021-08-01","conditions":"Cardiovascular Events, Type2 Diabetes, Renal Disease","enrollment":781430},{"nctId":"NCT05390892","phase":"PHASE4","title":"PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2022-09-26","conditions":"Type2Diabetes, ASCVD","enrollment":6000},{"nctId":"NCT05090358","phase":"PHASE2","title":"Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-10-08","conditions":"Breast Cancer, Breast Cancer Stage IV, Metastatic Breast Cancer","enrollment":15},{"nctId":"NCT07188545","phase":"","title":"Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ohio State University","startDate":"2025-09-15","conditions":"Cardiovascular Kidney Metabolic Syndrome","enrollment":23280000},{"nctId":"NCT04662723","phase":"PHASE4","title":"Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy.","status":"RECRUITING","sponsor":"Fondazione Schena","startDate":"2023-05-01","conditions":"Glomerulonephritis, Immunoglobulin A Nephropathy","enrollment":878},{"nctId":"NCT06291155","phase":"PHASE4","title":"Mechanism of SGLT2 Inhibition in the Kidney","status":"RECRUITING","sponsor":"University of Michigan","startDate":"2024-01-01","conditions":"Type 2 Diabetes, Diabetic Kidney Disease","enrollment":20},{"nctId":"NCT04304261","phase":"PHASE3","title":"Effects of SGLT2i on the Cognitive Function in T2DM Patient (ESCDP)","status":"COMPLETED","sponsor":"Third Military Medical University","startDate":"2021-07-01","conditions":"Diabetes Mellitus, Type 2, Cognitive Functions Confusion","enrollment":100},{"nctId":"NCT03918148","phase":"","title":"Gliflozins and Cardiovascular Risk Factors in Type 2 Diabetes (GIOIA)","status":"COMPLETED","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2018-01-15","conditions":"Type 2 Diabetes Mellitus","enrollment":1150},{"nctId":"NCT06187493","phase":"NA","title":"Treatment of Patients With Diabetic Kidney Disease","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2024-01-01","conditions":"Diabetic Kidney Disease","enrollment":70},{"nctId":"NCT04700839","phase":"PHASE4","title":"SGLT2 Inhibitors in Patients With PCOS","status":"COMPLETED","sponsor":"Shanghai 10th People's Hospital","startDate":"2020-05-01","conditions":"Polycystic Ovary Syndrome","enrollment":68},{"nctId":"NCT02653209","phase":"PHASE4","title":"TriMaster: Study of a DPP4 Inhibitor, SGLT2 Inhibitor and Thiazolidinedione as Third Line Therapy in Patients With Type 2 Diabetes.","status":"COMPLETED","sponsor":"Royal Devon and Exeter NHS Foundation Trust","startDate":"2016-11-01","conditions":"Type 2 Diabetes","enrollment":525},{"nctId":"NCT03917758","phase":"NA","title":"Antidiuretic Function Before and During Treatment With SGLT2 Inhibitors","status":"UNKNOWN","sponsor":"University of Turin, Italy","startDate":"2018-10-10","conditions":"Diabetes Mellitus, Type 2, Arterial Hypertension, Body Weight Changes","enrollment":30},{"nctId":"NCT04196231","phase":"PHASE4","title":"Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND)","status":"COMPLETED","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2019-11-27","conditions":"Type 2 Diabetes","enrollment":258},{"nctId":"NCT04184947","phase":"","title":"Cardiovascular Outcomes SGLT-2 Inhibitors Versus GLP-1 Receptor Agonists","status":"COMPLETED","sponsor":"University of Padova","startDate":"2014-03-01","conditions":"Type 2 Diabetes","enrollment":10000},{"nctId":"NCT03249506","phase":"","title":"Cardiovascular Outcomes in Participants With Type 2 Diabetes Mellitus (T2DM)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2016-05-12","conditions":"Diabetes Mellitus, Type 2","enrollment":25358},{"nctId":"NCT02857764","phase":"","title":"Sodium-glucose Co-transporter 2 (SGLT2) Inhibitor Risk of Below-Knee Lower Extremity Amputation: A Retrospective Cohort Study Using a Large Claims Database in the United States","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2016-02-15","conditions":"Diabetes Mellitus, Type 2","enrollment":127690}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":356,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Invokana"],"phase":"marketed","status":"active","brandName":"Canagliflozin - SGLT2i","genericName":"Canagliflozin - SGLT2i","companyName":"Royal Devon and Exeter NHS Foundation Trust","companyId":"royal-devon-and-exeter-nhs-foundation-trust","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Canagliflozin blocks the SGLT2 transporter in the kidney to reduce glucose reabsorption, allowing excess glucose to be excreted in urine and lowering blood sugar. Used for Type 2 diabetes mellitus, Reduction of cardiovascular death and hospitalization for heart failure in patients with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}